Time‐varying age‐ and CD4‐stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium

• Published in: Journal of the International AIDS Society 2020-10, Vol.23 (10), p.e25617-n/a
• Main Authors: Desmonde, Sophie, Neilan, Anne M, Musick, Beverly, Patten, Gabriela, Chokephaibulkit, Kulkanya, Edmonds, Andrew, Duda, Stephany N, Malateste, Karen, Wools‐Kaloustian, Kara, Ciaranello, Andrea L, Davies, Mary‐Ann, Leroy, Valériane
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adolescent; adolescents; Adult; Africa, Southern - epidemiology; Age; AIDS; Anti-HIV Agents - therapeutic use; Antiretroviral drugs; Antiviral agents; Asia - epidemiology; Care and treatment; Caribbean Region - epidemiology; CD4 Lymphocyte Count; Central America - epidemiology; Child; Child, Preschool; Children & youth; Cohort Studies; Consortia; Dosage and administration; Drug therapy; Female; Highly active antiretroviral therapy; HIV; HIV infection in children; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Infections - mortality; HIV Infections - transmission; HIV patients; Human health and pathology; Human immunodeficiency virus; Humans; Incidence; Infant; Infant, Newborn; Infectious diseases; Laboratories; Life Sciences; Male; Mortality; paediatrics; Patient outcomes; Pediatric HIV infections; Pediatric research; Pediatrics; Perinatal infection; Prevention; Risk factors; Santé publique et épidémiologie; severe morbidity; South America - epidemiology; Teenagers; Tuberculosis; World Health Organization; Young Adult
• ISSN: 1758-2652; 1758-2652
• DOI: 10.1002/jia2.25617

Introduction Evaluating outcomes of paediatric patients with HIV provides crucial data for clinicians and policymakers. We analysed mortality and clinical events rates among children, adolescents, and youth with perinatally acquired HIV (PHIV) aged 0 to 24 years stratified by time‐varying age and CD4, before and after antiretroviral therapy (ART), in the paediatric IeDEA multiregional collaboration (East, West, Central and Southern Africa, Asia‐Pacific, and Central/South America and the Caribbean). Methods ART‐naïve children with HIV enrolled before age 10 (proxy for perinatal infection) at IeDEA sites between 2004 and 2016, with ≥1 CD4 measurement during follow‐up were included. We estimated incidence rates (IR) and 95% confidence intervals (95% CI) of mortality and first occurrence of WHO‐4 and WHO‐3 events, excluding tuberculosis, during person‐years (PY) spent within different age (